Mammalian Cell Fermentation Technology Market Size & Share, by Type (Chinese Hamster Ovary [CHO] Cell Fermentation, Human Embryonic Kidney [HEK] Cell Fermentation, Baby Hamster Kidney [BHK] Cell Fermentation); Application (Monoclonal Antibodies, Recombinant Proteins, Vaccines, Others); End-Use (CMOs & CDMOs, Biopharmaceutical Companies) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 5561
  • Published Date: Jan 23, 2024
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2024-2036

Mammalian Cell Fermentation Technology Market size is poised to cross USD 105 Billion by the end of 2036, expanding around 9% CAGR during the forecast period, i.e., 2024-2036. In the year 2023, the industry size of mammalian cell fermentation technology was about USD 43 Billion. The major element to dominate the market revenue is growing cases of COVID-19. Globally COVID-19 cases were close to 767 million as of June 13, 2023. Hence, numerous businesses have shifted their efforts on developing COVID-19 treatments and vaccinations in the wake of the pandemic which is further increasing need for mammalian cell fermentation technology. The increased need for mammalian cells for research and development has resulted in a noteworthy influence on the mammalian cell fermentation industry. 

Furthermore, mammalian cell systems have become popular in the biopharmaceutical business due to strict regulatory rules and safety standards. Since mammalian expression systems may generate big, complex proteins with post-translational modifications (PTMs; most notably glycosylation) the same to those produced in humans, hence further offering greater product consistency and quality, supporting mammalian cell fermentation technology market expansion.  

Mammalian Cell Fermentation Technology Market
Get more information on this report: Request Free Sample PDF

Mammalian Cell Fermentation Technology Market: Key Insights

Base Year


Forecast Year




Base Year Market Size (2023)

~ USD 43 Billion

Forecast Year Market Size (2036)

~ USD 105 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Mammalian Cell Fermentation Technology Sector: Growth Drivers and Challenges


Growth Drivers

  • Growth in Making of Personalized Medications - Recent years have seen a significant increase in the popularity of personalized medicine, due to the potential for less side effects and more successful therapies. The area of personalized medicine and mammalian cell fermentation technology combine in a profound and innovative way. Personalized medical's basic goal is to identify the optimal course of treatment for each individual patient. This usually means developing highly targeted therapeutics, including gene therapies, cell-based therapies, and monoclonal antibodies. The creation of these innovative medicines requires the fermentation of mammalian cells.
  • Advancement in Technology for Mammalian Cell Fermentation - Mammalian cell fermentation is growing more effective and scalable due to ongoing advancements in cell culture methods, medium compositions, and bioreactor architecture. For instance, in case of bioreactors the utilization of single use bioreactors is growing. Most fermentation operations performed nowadays take place in bioreactors constructed from conventional materials including stainless steel. However, disposable technology is gaining popularity as a means to improve flexibility, and reducing batch change-over time. These systems are rapidly establishing themselves as another important technological advancement in the fields of pharmaceutical applications and mammalian cell culture. Furthermore, when single-use bioreactors with rigorous qualification and validation processes are used with very potent biopharmaceutical ingredients, the risk of cross-contamination is decreased and process safety is improved. As a result, the market is observing growth over the coming years.
  • Rising Chronic Disease - According to the World Health Organization, noncommunicable diseases (NCDs) account for 41 million annual deaths worldwide, or 74% of all fatalities. The ability to regulate gene expression has been studied in mammalian cells, both in vitro and in vivo. It is possible to modify gene regulation in intact animals as well as in cultured cardiomyocytes, with potential applications in the management of chronic human illness. Hence, the demand for mammalian cell fermentation technology is projected to have significant growth.


  • High Cost of Capital - Mammalian cell fermentation technology is crucial to the biotechnology and pharmaceutical industries, however one major obstacle to its growth is the high capital costs associated with it. Smaller companies and startups often find it difficult to enter the mammalian cell fermentation industry due to the substantial financial investment required to create and operate these facilities. Furthermore, the primary driver of these capital costs is the need for specialized infrastructure. Mammalian cell fermentation usually takes place within large, complex tanks called bioreactors, which are designed to provide a controlled environment for cell growth and product synthesis. Temperature, pH, oxygenation, and agitation are just a few of the parameters that these bioreactors must meet carefully. Building and certifying these bioreactors to meet regulations would come at a high financial cost. Another aspect pushing up capital expenses is the need for highly skilled workers. Facilities for the fermentation of mammalian cells must be run and maintained by personnel skilled in cell culture techniques, bioprocess engineering, and regulatory compliance. The competitive salaries that these professionals command further increase the overall cost.
  • Strict Regulatory Challenges
  • Lack of Knowledge Regarding New Technology.

Mammalian Cell Fermentation Technology Segmentation

Type (Chinese Hamster Ovary [CHO] Cell Fermentation, Human Embryonic Kidney [HEK] Cell Fermentation, Baby Hamster Kidney [BHK] Cell Fermentation, Murine Myeloma Cell Fermentation)

The Chinese hamster ovary (CHO) cell fermentation segment in the mammalian cell fermentation technology market is estimated to capture share of about 40% over the coming years. For many years, Chinese hamster ovary cells, or CHO cells, have been cultivated and modified for use in pharmaceutical biotechnology and molecular biology. Furthermore, this fermentation process is extensively utilized in manufacturing monoclonal antibodies and therapeutic proteins. Furthermore, therapeutics proteins are used to treat HIV. Therefore, with the growing prevalence of HIV the segment is growing. In 2022, there were about 39 million HIV-positive individuals in the world. Of them, 1.5 million were children under the age of fifteen, and 37.5 million were adults. Furthermore, 53% of the population was female. Additionally, the capacity of Chinese hamster ovary cells to generate proteins with complex glycosylations, or post-translational modifications (PTMs), that resemble those produced by humans, is the main advantage of using them as mammalian cell line expression platforms. Other common in vitro cell types, including E. coli, cannot produce recombinant proteins of this high quality.

End-Use (CMOs & CDMOs, Biopharmaceutical Companies, Academic & Research Institutes)

The CMOs & CDMOs segment in the mammalian cell fermentation technology market is set to capture the highest share of 50% during the forecast period. This is since smaller companies generate most of the innovation in the bioprocess industry yet lack the capacity, experienced personnel, and resources required for the commercialization of these products, CMOs and CDMOs are fast becoming the go-to option for makers of biotherapeutics. Hence, with the growing small companies in the field of biotherapeutic the segment is anticipated to rise.

Our in-depth analysis of the global mammalian cell fermentation technology market includes the following segments:


  • Chinese Hamster Ovary [CHO] Cell Fermentation
  • Human Embryonic Kidney [HEK] Cell Fermentation
  • Baby Hamster Kidney [BHK] Cell Fermentation
  • Murine Myeloma Cell Fermentation


  • Monoclonal Antibodies
  • Recombinant Proteins
  • Vaccines
  • Hormones
  • Enzymes


  • CMOs & CDMOs
  • Biopharmaceutical Companies
  • Academic & Research Institutes

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Mammalian Cell Fermentation Technology Industry - Regional Synopsis

North American Market Forecasts

The North America mammalian cell fermentation technology market is predicted to capture the largest share of about 35% over the forecast period. This growth of the market in this region is poised to be dominated by rising investment in biotechnology. For instance, in order to increase the use of biomanufacturing for antibiotics, active pharmaceutical ingredients (APIs), and other critical starting materials required to make life-saving drugs and combat pandemics, the Department of Health and Human Services will invest over USD 39 million. Furthermore, there are number of various key biopharmaceutical companies in this region focusing in the field of mammalian cell hence boosting the market growth. 

APAC Market Analysis

The mammalian cell fermentation technology market in Asia Pacific is predicted to have notable growth over the forecast period. The major factor to influence the market expansion is growth in patient traveling for medical treatment in this region. This is since, Asian nations are frequently chosen as medical tourism destinations because of how reasonably priced their medical services are. Numerous variables, including reduced living expenses, decreased operating costs in healthcare facilities, and favorable foreign exchange rates, are responsible for this affordability. Therefore, the market for mammalian cell fermentation is projected to grow in this region.  

Research Nester
Mammalian Cell Fermentation Technology Market size
Get more information on this report: Request Free Sample PDF

Top Featured Companies Dominating the Mammalian Cell Fermentation Technology Landscape

    • Shanghai Henlius Biotech, Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Evonik
    • Thermo Fisher Scientific Inc.
    • General Electric
    • Danaher Corporation
    • Merck KGaA
    • Sartorius AG
    • Amgen, Inc.
    • Eppendorf AG
    • Pall Corporation


In The News

  • Shanghai Henlius Biotech, Inc. stated that it has signed an exclusive licence deal with Fosun Pharma to commercialise the anti-PD-1 monoclonal antibody (mAb) HANSIZHUANG, which Henlius independently created, in the US. The conditions of the deal state that Henlius will continue to be in charge of development, manufacture, and supply, while Fosun Pharma will have the authority to commercialise HANSIZHUANG in the US following approval.
  • A highly pure cystine peptide is now available from Evonik to help with formulation issues with cell culture media and other methods that are utilized in the creation and manufacturing of biopharmaceuticals. Globally accessible, cQrex AC is a chemically defined, highly soluble source of L-cystine that allows cells to get enough of this essential amino acid. 


Author Credits:  Radhika Gupta, Shivam Bhutani

  • Report ID: 5561
  • Published Date: Jan 23, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The major factors driving the growth of the market are growth in making of personalized medications, advancement in technology for mammalian cell fermentation, and rising chronic disease.

The market size of mammalian cell fermentation technology is anticipated to attain a CAGR of 9% over the forecast period, i.e., 2024-2036.

The major players in the market are Shanghai Henlius Biotech, Inc., Evonik, Thermo Fisher Scientific Inc., General Electric, and others.

The Chinese hamster ovary (CHO) cell fermentation segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the North America region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Mammalian Cell Fermentation Technology Market Report Scope

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying